Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans

Bryan Larsen, Marija Petrovic, Francesco DeSeta

Research output: Contribution to journalArticle

Abstract

© 2017 Springer Science+Business Media B.V. Clinical use of boric acid as a topical antifungal in women who have failed standard antifungal therapy with azole drugs has been used sporadically for decades. Our previous in vitro work showing inhibition of Candida albicans growth was conducted on clinical isolates without antifungal drug susceptibility profiling. Here, we report that boric acid restricts growth of drug-resistant Candida albicans and inhibits hyphal growth and diminishes cell volume. The availability of over-the-counter organoboron compounds intended for use as oral nutritional supplements led us to determine if these also were inhibitory toward resistant Candida and show here that they also possess antifungal activity. Candida glabrata was also found to be inhibited by boric acid and organoboron compounds. Further development of organoboron compounds as topical therapeutics is of potential value.
Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalMycopathologia
DOIs
Publication statusAccepted/In press - Oct 9 2017

Keywords

  • Boric acid
  • Candida albicans
  • Candida glabrata
  • Drug resistant
  • Organoboron

Fingerprint Dive into the research topics of 'Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans'. Together they form a unique fingerprint.

  • Cite this